Improving the Quality of Multiple Myeloma Treatment with Patient Care Plans: Pilot Testing the Impact of Continuing Education and Care Planning on Symptom Management
FOR REFERENCE ONLY
Release Date: April 24, 2015 Valid for credit through December 31, 2016
ESTIMATED TIME TO COMPLETE ACTIVITY:
This activity has been designed to meet the educational needs of hematologists, medical oncologists, physician assistants, nurse practitioners, clinical nurse specialists, and oncology nurses involved in the care of patients with multiple myeloma.
Upon completion of this program, participants should be better able to:
- Select an individualized treatment strategy for patients with multiple myeloma based on genetic testing and biomarker expression
- Evaluate evidence-based strategies for induction, consolidation, and maintenance therapy for multiple myeloma
- Implement individualized plans for evidence-based management of side effects commonly associated with multiple myeloma
- Select patients who meet criteria for participation in ongoing multiple myeloma clinical research
- Provide appropriate care and counsel for patients and their families
- Physicians – maximum of 4.75 AMA PRA Category 1 Credits™
- Nurses – 4.7 contact hours
All other healthcare professionals completing this course will be issued a statement of participation
Beth Faiman, PhD, RN, APRN, BC, AOCN
Cleveland Clinic Taussig Cancer Center
Rafael Fonseca, MD
Mayo Clinic, Arizona
Kenneth Anderson, MD
Dana Farber Cancer Institute/Harvard Medical School
Jonathan Kaufman, MD
Winship Cancer Center at Emory University
Joseph Tariman, MD
Tiffany Richards, ANP, AOCN
MD Anderson Cancer Center
Patrice Mangan, CNP
University of Pennsylvania
Charise Gleason, MSN, RN, NP-BC, AOCNP
Winship Cancer Center at Emory University
Sandra Kurtin, MSN, CNP
University of Arizona Cancer Center
PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Carevive Health, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
This educational activity for 4.7 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Beth Faiman, PhD, RN, APRN, BC, AOCN||Consulting Fees,Celgene Corporation,Takeda Oncology, Onyx; Contracted Research,Celgene Corporation, Takeda Oncology, Onyx.|
|Kenneth Anderson, MD||Consulting Fees,Celgene Corporation,Takeda Oncology, Bristol-MyersSquibb, Gilead Sciences,Sanofi-aventis; Ownership Interest, founder Acetylon/Oncoprep.|
|Rafael Fonseca, MD||Intellectual property, FISH probes formyeloma; Consulting Fees,Celgene Corporation,Bristol-Myers Squibb, Eli Lilly and Company, Onyx, Binding Site; Speakers’ Bureaus,Takeda Oncology, Bayer, Novartis, Applied Bioscience, Amgen; Contracted Research,Celgene Corporation, Onyx.|
|Charise Gleason, MSN, RN, NP-BC, AOCNP||Has no real or apparent conflicts of interest to report.|
|Jonathan Kaufman, MD||Consulting Fees,Celgene Corporation,Novartis,Takeda Oncology, Onyx, Spectrum;Contracted Research, Onyx, Novartis, Merck & Co.|
|Sandra Kurtin, MSN, CNP||Consulting Fees, Celgene Corporation, Takeda Oncology, Onyx, Novartis.|
|Patrice Mangan, CNP||Consulting Fees,Novartis, Bristol-MyersSquibb,Celgene Corporation; Speakers’ Bureaus,Onyx, Celgene Corporation, Takeda Oncology.|
|Tiffany Richards, ANP, AOCN||Consulting Fees, Celgene, Onyx.|
|Joseph Tariman, MD||Has no real or apparent conflicts of interest to report.|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, MSN, RN, CCMEP, and Judi Smelker-Mitchek, RN, BSN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following Carevive Health, Inc. planners and managers reported the following: Timothy J. DiChiara, PhD, Consulting Fees, Gilead Sciences; Karen Hammelef, DNP, RN, Speakers’ Bureau, Novartis Pharmaceuticals Corporation.
INSTRUCTIONS FOR PARTICIPATION AND CREDIT
There are no fees for participating and receiving credit for this activity. During the period April 24, 2015 through April 24, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form.
To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded.
If you successfully complete the post-test (score of 75% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.
HARDWARE AND SOFTWARE REQUIREMENTS
CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.